CDKN2B-AS1 and type 2 diabetes mellitus: As a genomic hotspot of CAD and T2DM, we aimed toexamine the expression profile of ANRIL in CAD+ versusCADpatients with T2DM to identify whether ANRILcould be a potential target for treatment or biomarker toidentifying T2DM patients with CAD.